Shares of Solventum Corp. shed 4.42% to $79.75 Friday, on what proved to be an all-around positive trading session for the ...

Solventum surpassed fourth-quarter revenue and earnings expectations while facing challenges in segments and regulatory ...

The addition of Solventum’s business provides a strategic fit with Thermo Fisher and will create value for customers, according to Marc N. Casper, chairman, president, and CEO of Thermo Fisher.

Solventum (NYSE:SOLV) yesterday announced fourth-quarter results that came in ahead of the consensus forecast on Wall Street.

Wells Fargo raised the firm’s price target on Solventum (SOLV) to $75 from $73 and keeps an Equal Weight rating on the shares. The Q4 beat was ...

Piper Sandler raised the firm’s price target on Solventum (SOLV) to $84 from $75 and keeps a Neutral rating on the shares. The firm notes ...

M spin-off Solventum forecast annual profit above analyst estimates on Thursday, betting on strong sales of its wound care and surgical sterilization products.

Shares of Solventum jumped Tuesday and led S&P 500 gainers intraday after medical device maker Thermo Fisher Scientific said ...

Solventum faces significant challenges in its turnaround, including slow-growing core businesses, share loss, and margin ...

Solventum's $4.1B divestment to Thermo Fisher enhances financial stability, boosts EPS, and strengthens its long-term growth ...

Solventum Corp (SOLV) reports robust earnings per share and strategic advancements, while navigating separation complexities and market headwinds.

(Reuters) -Contract drug manufacturer Thermo Fisher Scientific said on Tuesday it will buy Solventum's purification and ...